^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
aDC1 vaccine
i
Other names: aDC1 vaccine, alphaDC1, alpha-type-1 polarized dendritic cells, autologous alpha-DC1/TBVA vaccine, αDC1-TBVA vaccine
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Roswell Park, University of Pittsburgh
Drug class:
Immunostimulant
Related drugs:
28d
Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer (clinicaltrials.gov)
P2, N=19, Not yet recruiting, Roswell Park Cancer Institute | Trial completion date: May 2026 --> Oct 2026 | Trial primary completion date: May 2026 --> Oct 2026
Trial completion date • Trial primary completion date • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 negative
|
Keytruda (pembrolizumab) • aDC1 vaccine
3ms
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma (clinicaltrials.gov)
P2, N=24, Recruiting, Roswell Park Cancer Institute | Suspended --> Recruiting
Enrollment open
|
CD8 (cluster of differentiation 8)
|
CD8 positive
|
Intron A (interferon α-2b) • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral
5ms
Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer (clinicaltrials.gov)
P2, N=19, Not yet recruiting, Roswell Park Cancer Institute | Trial completion date: Sep 2025 --> Jan 2026 | Trial primary completion date: Sep 2025 --> Jan 2026
Trial completion date • Trial primary completion date • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 negative
|
Keytruda (pembrolizumab) • aDC1 vaccine
6ms
Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
P1/2, N=0, Withdrawn, Roswell Park Cancer Institute | N=18 --> 0 | Not yet recruiting --> Withdrawn
Enrollment change • Trial withdrawal • Immune cell
|
CD8 (cluster of differentiation 8)
|
aDC1 vaccine
6ms
Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
P1/2, N=18, Not yet recruiting, Roswell Park Cancer Institute | Trial completion date: Aug 2025 --> Dec 2025 | Trial primary completion date: Aug 2025 --> Dec 2025
Trial completion date • Trial primary completion date • Immune cell
|
CD8 (cluster of differentiation 8) • NKG2D (killer cell lectin like receptor K1)
|
aDC1 vaccine
7ms
Targeting the pericyte antigen DLK1 with an alpha type-1 polarized dendritic cell vaccine results in tumor vascular modulation and protection against colon cancer progression. (PubMed, Front Immunol)
Our pre-clinical data demonstrate the αDC1 vaccine's ability to induce anti-tumor effects by facilitating cytotoxic T lymphocyte activity and ablating the tumor vasculature. This work, overall, provides a foundation to further interrogate immune-mediated mechanisms of protection in order to help devise efficacious αDC1-based strategies for patients with CRC.
Journal
|
DLK1 (Delta Like Non-Canonical Notch Ligand 1)
|
DLK1 expression
|
aDC1 vaccine
9ms
Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer (clinicaltrials.gov)
P2, N=19, Not yet recruiting, Roswell Park Cancer Institute | Trial completion date: May 2025 --> Sep 2025 | Trial primary completion date: May 2025 --> Sep 2025
Trial completion date • Trial primary completion date • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 negative
|
Keytruda (pembrolizumab) • aDC1 vaccine
11ms
Autologous Dendritic Cell Vaccine in Kidney Cancer (clinicaltrials.gov)
P2a, N=42, Recruiting, Jodi Maranchie | Not yet recruiting --> Recruiting
Enrollment open • Combination therapy
|
CD31 (Platelet and endothelial cell adhesion molecule 1) • HES1 • NRP1 (Neuropilin 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
|
Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • aDC1 vaccine
1year
Phase IIa study of αDC1 vaccines targeting HER2/HER3 combined with pembrolizumab in patients with asymptomatic brain metastasis from triple negative breast cancer or HER2+ breast cancer. (ASCO 2023)
Exploratory endpoints include changes in intratumoral biomarkers (CTLs, PDL1, chemokines) in pre- and post-treatment peripheral tumor biopsies and immune changes in the blood. Clinical trial information: NCT04348747.
Clinical • P2a data • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CCR5 (C-C Motif Chemokine Receptor 5) • CXCL11 (C-X-C Motif Chemokine Ligand 11) • CXCR3 (C-X-C Motif Chemokine Receptor 3)
|
HER-2 overexpression • ERBB3 overexpression • CCR5 expression
|
Keytruda (pembrolizumab) • aDC1 vaccine
1year
Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer (clinicaltrials.gov)
P2, N=19, Not yet recruiting, Roswell Park Cancer Institute | Trial completion date: Dec 2025 --> May 2025
Trial completion date • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 negative
|
Keytruda (pembrolizumab) • aDC1 vaccine
1year
Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer (clinicaltrials.gov)
P2, N=19, Not yet recruiting, Roswell Park Cancer Institute | Trial primary completion date: Dec 2024 --> Apr 2025
Trial primary completion date • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 negative
|
Keytruda (pembrolizumab) • aDC1 vaccine
over1year
A Cytomegalovirus-Directed Vaccine (CMV-alphaDC1) for Preventing Cytomegalovirus Infection or Reactivation in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov)
P1b, N=0, Withdrawn, Roswell Park Cancer Institute | N=12 --> 0 | Not yet recruiting --> Withdrawn
Enrollment change • Trial withdrawal
|
IFNG (Interferon, gamma)
|
aDC1 vaccine
over1year
Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
P1/2, N=18, Not yet recruiting, Roswell Park Cancer Institute | Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
Trial completion date • Trial primary completion date • Immune cell
|
CD8 (cluster of differentiation 8) • NKG2D (killer cell lectin like receptor K1)
|
aDC1 vaccine
over1year
Type I-Polarized Autologous Dendritic Cell Vaccine With Tumor Blood Vessel Antigen-Derived Peptides in Metastatic Breast Cancer Patients (clinicaltrials.gov)
P1, N=18, Completed, Joseph Baar, MD, PhD | Trial completion date: Oct 2019 --> Jul 2022
Trial completion date • Metastases
|
IFNG (Interferon, gamma)
|
gemcitabine • aDC1 vaccine
over1year
Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer (clinicaltrials.gov)
P2, N=19, Not yet recruiting, Roswell Park Cancer Institute | Phase classification: P1/2 --> P2
Phase classification • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 negative
|
Keytruda (pembrolizumab) • aDC1 vaccine
over1year
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines (clinicaltrials.gov)
P1/2, N=25, Suspended, Roswell Park Cancer Institute | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
Trial completion date • Trial primary completion date
|
CD4 (CD4 Molecule)
|
cisplatin • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral
over1year
Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer (clinicaltrials.gov)
P1/2, N=19, Not yet recruiting, Roswell Park Cancer Institute
New P1/2 trial • New P2 trial
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 negative
|
Keytruda (pembrolizumab) • aDC1 vaccine
Share via
